REGENXBIO INC (RGNX) Fundamental Analysis & Valuation

NASDAQ:RGNX • US75901B1070

Current stock price

9.49 USD
+0.3 (+3.26%)
At close:
9.67 USD
+0.18 (+1.9%)
After Hours:

This RGNX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. RGNX Profitability Analysis

1.1 Basic Checks

  • RGNX had negative earnings in the past year.
  • In the past year RGNX has reported a negative cash flow from operations.
  • In the past 5 years RGNX reported 4 times negative net income.
  • In the past 5 years RGNX reported 4 times negative operating cash flow.
RGNX Yearly Net Income VS EBIT VS OCF VS FCFRGNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M -200M

1.2 Ratios

  • RGNX has a Return On Assets (-42.80%) which is comparable to the rest of the industry.
  • The Return On Equity of RGNX (-188.72%) is worse than 68.67% of its industry peers.
Industry RankSector Rank
ROA -42.8%
ROE -188.72%
ROIC N/A
ROA(3y)-45.81%
ROA(5y)-31.92%
ROE(3y)-120.24%
ROE(5y)-79.66%
ROIC(3y)N/A
ROIC(5y)N/A
RGNX Yearly ROA, ROE, ROICRGNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150

1.3 Margins

  • Looking at the Gross Margin, with a value of 88.09%, RGNX belongs to the top of the industry, outperforming 89.36% of the companies in the same industry.
  • RGNX's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for RGNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 88.09%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y19.48%
GM growth 5Y2.75%
RGNX Yearly Profit, Operating, Gross MarginsRGNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. RGNX Health Analysis

2.1 Basic Checks

  • RGNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • RGNX has more shares outstanding than it did 1 year ago.
  • RGNX has more shares outstanding than it did 5 years ago.
  • RGNX has a worse debt/assets ratio than last year.
RGNX Yearly Shares OutstandingRGNX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
RGNX Yearly Total Debt VS Total AssetsRGNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • Based on the Altman-Z score of -3.01, we must say that RGNX is in the distress zone and has some risk of bankruptcy.
  • RGNX has a Altman-Z score (-3.01) which is comparable to the rest of the industry.
  • RGNX has a Debt/Equity ratio of 1.43. This is a high value indicating a heavy dependency on external financing.
  • RGNX has a Debt to Equity ratio of 1.43. This is in the lower half of the industry: RGNX underperforms 78.14% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.43
Debt/FCF N/A
Altman-Z -3.01
ROIC/WACCN/A
WACC8.86%
RGNX Yearly LT Debt VS Equity VS FCFRGNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

  • RGNX has a Current Ratio of 2.38. This indicates that RGNX is financially healthy and has no problem in meeting its short term obligations.
  • RGNX's Current ratio of 2.38 is on the low side compared to the rest of the industry. RGNX is outperformed by 73.50% of its industry peers.
  • A Quick Ratio of 2.38 indicates that RGNX has no problem at all paying its short term obligations.
  • RGNX has a Quick ratio of 2.38. This is in the lower half of the industry: RGNX underperforms 69.83% of its industry peers.
Industry RankSector Rank
Current Ratio 2.38
Quick Ratio 2.38
RGNX Yearly Current Assets VS Current LiabilitesRGNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. RGNX Growth Analysis

3.1 Past

  • RGNX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.54%, which is quite good.
  • Looking at the last year, RGNX shows a very strong growth in Revenue. The Revenue has grown by 104.54%.
  • The Revenue has been growing slightly by 1.97% on average over the past years.
EPS 1Y (TTM)17.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.71%
Revenue 1Y (TTM)104.54%
Revenue growth 3Y14.78%
Revenue growth 5Y1.97%
Sales Q2Q%43%

3.2 Future

  • RGNX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.96% yearly.
  • RGNX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 37.29% yearly.
EPS Next Y32.92%
EPS Next 2Y11.18%
EPS Next 3Y14.86%
EPS Next 5Y24.96%
Revenue Next Year42.69%
Revenue Next 2Y30.35%
Revenue Next 3Y40.44%
Revenue Next 5Y37.29%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RGNX Yearly Revenue VS EstimatesRGNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
RGNX Yearly EPS VS EstimatesRGNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5

More info and screens

Find the best growth stocksShow best growing peers

0

4. RGNX Valuation Analysis

4.1 Price/Earnings Ratio

  • RGNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RGNX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RGNX Price Earnings VS Forward Price EarningsRGNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RGNX Per share dataRGNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as RGNX's earnings are expected to grow with 14.86% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.18%
EPS Next 3Y14.86%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RGNX Dividend Analysis

5.1 Amount

  • RGNX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RGNX Fundamentals: All Metrics, Ratios and Statistics

REGENXBIO INC

NASDAQ:RGNX (4/17/2026, 8:00:02 PM)

After market: 9.67 +0.18 (+1.9%)

9.49

+0.3 (+3.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-05
Earnings (Next)05-06
Inst Owners79.95%
Inst Owner Change-0.05%
Ins Owners7.55%
Ins Owner Change17.14%
Market Cap489.78M
Revenue(TTM)170.44M
Net Income(TTM)-193.88M
Analysts84.21
Price Target30.26 (218.86%)
Short Float %14.39%
Short Ratio7.52
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.71%
Min EPS beat(2)-33.31%
Max EPS beat(2)9.88%
EPS beat(4)1
Avg EPS beat(4)-30.51%
Min EPS beat(4)-75.63%
Max EPS beat(4)9.88%
EPS beat(8)3
Avg EPS beat(8)-11.74%
EPS beat(12)5
Avg EPS beat(12)-9.2%
EPS beat(16)5
Avg EPS beat(16)-10.76%
Revenue beat(2)1
Avg Revenue beat(2)1.09%
Min Revenue beat(2)-18.65%
Max Revenue beat(2)20.83%
Revenue beat(4)1
Avg Revenue beat(4)-9.44%
Min Revenue beat(4)-25.51%
Max Revenue beat(4)20.83%
Revenue beat(8)2
Avg Revenue beat(8)-11.17%
Revenue beat(12)3
Avg Revenue beat(12)-16.57%
Revenue beat(16)4
Avg Revenue beat(16)-14.93%
PT rev (1m)-1.62%
PT rev (3m)-9.47%
EPS NQ rev (1m)-8.75%
EPS NQ rev (3m)-323.7%
EPS NY rev (1m)5.76%
EPS NY rev (3m)14.17%
Revenue NQ rev (1m)2.38%
Revenue NQ rev (3m)-66.05%
Revenue NY rev (1m)0.77%
Revenue NY rev (3m)-8.73%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.87
P/FCF N/A
P/OCF N/A
P/B 4.77
P/tB 4.77
EV/EBITDA N/A
EPS(TTM)-3.76
EYN/A
EPS(NY)-2.52
Fwd EYN/A
FCF(TTM)-2.45
FCFYN/A
OCF(TTM)-2.4
OCFYN/A
SpS3.3
BVpS1.99
TBVpS1.99
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -42.8%
ROE -188.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 88.09%
FCFM N/A
ROA(3y)-45.81%
ROA(5y)-31.92%
ROE(3y)-120.24%
ROE(5y)-79.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y19.48%
GM growth 5Y2.75%
F-Score4
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity 1.43
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.46%
Cap/Sales 1.42%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.38
Quick Ratio 2.38
Altman-Z -3.01
F-Score4
WACC8.86%
ROIC/WACCN/A
Cap/Depr(3y)29.33%
Cap/Depr(5y)240.61%
Cap/Sales(3y)5.13%
Cap/Sales(5y)12.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.71%
EPS Next Y32.92%
EPS Next 2Y11.18%
EPS Next 3Y14.86%
EPS Next 5Y24.96%
Revenue 1Y (TTM)104.54%
Revenue growth 3Y14.78%
Revenue growth 5Y1.97%
Sales Q2Q%43%
Revenue Next Year42.69%
Revenue Next 2Y30.35%
Revenue Next 3Y40.44%
Revenue Next 5Y37.29%
EBIT growth 1Y30.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year19.04%
EBIT Next 3Y16.92%
EBIT Next 5Y28.18%
FCF growth 1Y28.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y28.4%
OCF growth 3YN/A
OCF growth 5YN/A

REGENXBIO INC / RGNX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of REGENXBIO INC (RGNX) stock?

ChartMill assigns a fundamental rating of 2 / 10 to RGNX.


What is the valuation status for RGNX stock?

ChartMill assigns a valuation rating of 0 / 10 to REGENXBIO INC (RGNX). This can be considered as Overvalued.


How profitable is REGENXBIO INC (RGNX) stock?

REGENXBIO INC (RGNX) has a profitability rating of 2 / 10.


Can you provide the financial health for RGNX stock?

The financial health rating of REGENXBIO INC (RGNX) is 2 / 10.